Could a lower dose of an old antibiotic tame Drug-Resistant TB?
NCT ID NCT00664313
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests whether a low daily dose of the antibiotic linezolid, added to a personalized combination of other drugs, is safe and tolerable for people with multidrug-resistant tuberculosis (MDR-TB). Participants take either linezolid or a placebo for 16 weeks, alongside their regular treatment. The goal is to see if this approach can help control the infection with fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Linezolid (Zyvox)
- What this could lead to
- If successful, this could provide a safer, more tolerable treatment option for people with drug-resistant tuberculosis.
- What could go wrong
- This is an early-phase pilot study with only 36 participants, so results may not apply broadly. Linezolid can cause serious side effects like bone marrow suppression and nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King George V Hospital
Durban, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.